Annidis Corporation Receives Approval from China Food and Drug Administration for its RHA Gold Multi-Spectral Imaging Instrument

Annidis Corporation develops and markets imaging technologies to eye care professionals. The Company has developed a multi-spectral imaging (MSI) system for retinal and choroidal assessment (the RHA). The RHA provides eye-care professionals with a screening tool for early detection and diagnosis of a range of pathologies. The RHA is an ocular pathology management system that integrates MSI with analytic software and management of ocular pathologies, such as glaucoma, age-related macular degeneration and diabetic retinopathy. Its RHA collects and combines multi-spectral information. The RHA is a non-invasive instrument that uses MSI to take pictures of the retinal layers of eye. The images are then processed using the RHA Report software to reveal various layers in the back of the eye. The Company is also engaged in developing RHA Platinum, which is under development with beta units in clinical testing that allows doctors to visualize choroidal and retinal vasculature non-invasively.